Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition
J Cutan Med Surg
.
Sep/Oct 2017;21(2_suppl):2S-40S.
doi: 10.1177/1203475417722552.
Authors
Robert Bissonnette
1
,
Marc Bourcier
2
,
Melinda Gooderham
3
,
Chih-Ho Hong
4
,
Ian Landells
5
,
Charles Lynde
6
,
Kim Papp
3
,
Yves Poulin
7
,
Ronald Vender
8
,
Marni C Wiseman
9
Affiliations
1
1 Université de Montreal, Montreal, QC, Canada.
2
2 Université de Sherbrooke, Quebec, QC, Canada.
3
3 Queen's University, Kingston, ON, Canada.
4
4 University of British Columbia, Surrey, BC, Canada.
5
5 Memorial University of Newfoundland, St John's, NL, Canada.
6
6 University of Toronto, Toronto, ON, Canada.
7
7 Université de Laval, Quebec, QC, Canada.
8
8 McMaster University, Hamilton, ON, Canada.
9
9 University of Manitoba, Winnipeg, MB, Canada.
PMID:
29156950
DOI:
10.1177/1203475417722552
No abstract available
MeSH terms
Antibodies, Monoclonal / therapeutic use
Humans
Interleukin-17 / antagonists & inhibitors*
Psoriasis / drug therapy*
Substances
Antibodies, Monoclonal
IL17A protein, human
Interleukin-17